Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|July 1, 2001
- Pharmaceutical Technology-07-02-2001
- Volume 25
- Issue 7
The Role of USP in the Assessment of Microbiological Quality of Pharmaceuticals
USP ensures the microbiological quality of products by way of the development, proposal, and acceptance of general information chapters.
Advertisement
Articles in this issue
about 25 years ago
Musings on the Past 25 Yearsabout 25 years ago
Reflections on Changes at FDAabout 25 years ago
Deliver the Doseabout 25 years ago
Middle-European Pharmaceutics in a Changing Worldabout 25 years ago
The BCS: Where Do We Go From Here?about 25 years ago
From Inactive Ingredients to Pharmaceutical Excipientsabout 25 years ago
Am I Going Backwards?about 25 years ago
The Filter Scene: Old and Newabout 25 years ago
Catching Up with Expert Systemsabout 25 years ago
25 Years of Change in the Parenteral Technology FieldAdvertisement
Related to this article
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5